Bank of America Securities Remains a Buy on Crispr Therapeutics AG (CRSP)

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Crispr Therapeutics AG, with a price target of $86.00.

Easter Sale - 70% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Stranahan is a 4-star analyst with an average return of 5.0% and a 49.85% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Moderna, Novavax, and Crispr Therapeutics AG.

In addition to Bank of America Securities, Crispr Therapeutics AG also received a Buy from H.C. Wainwright’s Mitchell Kapoor in a report issued yesterday. However, on April 1, TipRanks – OpenAI reiterated a Hold rating on Crispr Therapeutics AG (NASDAQ: CRSP).

Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $864 thousand and a GAAP net loss of $130.61 million. In comparison, last year the company earned a revenue of $35 million and had a GAAP net loss of $37.31 million

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year. Most recently, in January 2026, Naimish Patel, the CMO of CRSP bought 1,508.00 shares for a total of $49,703.68.